Nuvation Bio (FRA:1E30) Other Current Liabilities: €11.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1E30 Nuvation Bio Inc FRA:1E30
18 GF Score
Price €6.62
! 4 Warning Signs
View Full Analysis

What is Nuvation Bio Other Current Liabilities?

Nuvation Bio FRA:1E30 +12.20% 18 Other Current Liabilities is €11.3 Mil as of Jun. 2026. GuruFocus rates FRA:1E30 with a GF Score™ of 18/100. The stock has 4 warning signs investors should review.

Nuvation Bio's other current liabilities for the quarter that ended in Jun. 2026 was €11.3 Mil.

Nuvation Bio's quarterly other current liabilities declined from Dec. 2025 (€27.7 Mil) to Mar. 2026 (€6.9 Mil) but then increased from Mar. 2026 (€6.9 Mil) to Jun. 2026 (€11.3 Mil).

Nuvation Bio's annual other current liabilities increased from Dec. 2023 (€4.0 Mil) to Dec. 2024 (€14.2 Mil) and increased from Dec. 2024 (€14.2 Mil) to Dec. 2025 (€27.7 Mil).

Nuvation Bio Other Current Liabilities Related Terms

Nuvation Bio Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Nuvation Bio's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuvation Bio Other Current Liabilities Chart

Nuvation Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 5.46 3.76 3.99 14.15 27.71

Nuvation Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 27.71 6.87 11.28
FRA:1E30
18GF Score
Nuvation Bio Inc FRA:1E30
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nuvation Bio Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €11.3 Mil mean?
Nuvation Bio (FRA:1E30) has a Other Current Liabilities of €11.3 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Nuvation Bio.
Is Nuvation Bio's Other Current Liabilities too high?
Nuvation Bio's current Other Current Liabilities is €11.3 Mil. Overall, Nuvation Bio has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's Other Current Liabilities compare to IOVA and SLS?
Nuvation Bio's Other Current Liabilities of €11.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Nuvation Bio. Nuvation Bio's current Other Current Liabilities is €11.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (FRA:1E30) has a current Other Current Liabilities of €11.3 Mil. The current Other Current Liabilities is €11.3 Mil. Nuvation Bio's overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Nuvation Bio (FRA:1E30), the current Other Current Liabilities is €11.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuvation Bio Business Description

Other Exchanges NUVB:USA
Address 1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
18GF Score

Get the complete analysis for FRA:1E30

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.62
Price